Q32 Bio Inc. (NASDAQ:QTTB) Given Average Rating of “Moderate Buy” by Analysts

Q32 Bio Inc. (NASDAQ:QTTB) has been given a consensus rating of “Moderate Buy” by the eight research firms that are covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $29.86.

A number of equities analysts have recently commented on QTTB shares. Oppenheimer reduced their price objective on shares of Q32 Bio from $80.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Leerink Partnrs downgraded Q32 Bio from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Piper Sandler lowered their price objective on Q32 Bio from $85.00 to $20.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Raymond James restated an “outperform” rating and set a $22.00 target price (down previously from $90.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $9.00 price target (down from $68.00) on shares of Q32 Bio in a research report on Wednesday, December 11th.

Hedge Funds Weigh In On Q32 Bio

Several institutional investors have recently bought and sold shares of the business. Values First Advisors Inc. acquired a new stake in shares of Q32 Bio in the third quarter valued at $33,000. Hussman Strategic Advisors Inc. bought a new position in shares of Q32 Bio in the fourth quarter worth about $36,000. Raymond James Financial Inc. acquired a new position in shares of Q32 Bio during the fourth quarter worth approximately $37,000. Drive Wealth Management LLC bought a new stake in shares of Q32 Bio during the fourth quarter valued at approximately $38,000. Finally, Savant Capital LLC acquired a new stake in shares of Q32 Bio in the fourth quarter valued at approximately $53,000. Institutional investors own 31.32% of the company’s stock.

Q32 Bio Stock Down 0.3 %

Shares of QTTB stock opened at $3.15 on Friday. Q32 Bio has a one year low of $2.90 and a one year high of $53.79. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a quick ratio of 6.53. The stock has a fifty day moving average price of $6.86 and a 200 day moving average price of $29.27. The stock has a market cap of $38.37 million, a P/E ratio of -0.22 and a beta of -0.32.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.